Ramantamig is the trispecific drug.
March 9
Has anyone had trispecific treatment for myeloma?
The search results don't mention trispecific treatments specifically. However, there's information about bispecific T-cell engagers (BiTEs), which are newer immunotherapy options for relapsed or refractory multiple myeloma.
BiTEs work by connecting your immune system's T Show Full Answer
Has anyone had trispecific treatment for myeloma?
The search results don't mention trispecific treatments specifically. However, there's information about bispecific T-cell engagers (BiTEs), which are newer immunotherapy options for relapsed or refractory multiple myeloma.
BiTEs work by connecting your immune system's T cells to myeloma cells, helping your body destroy the cancer. Several have been recently approved:
* Teclistamab (Tecvayli) - approved in 2022
* Elrexfio - approved in August 2023
* Linvoseltamab (Lynozyfic) - approved in July 2025
These treatments are typically used after you've tried at least four other therapies. They're "off-the-shelf" medications, meaning they're available more quickly than CAR T-cell therapy since they don't need to be custom-made for each person.
If you're hearing about trispecific treatments, they may be in clinical trials. Your oncology team can help you understand what newer treatment options might be available to you, including any clinical studies you might be eligible for.
March 9
Join
Your Privacy Choices
